The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement

• The percentage of patients with mean % Pain Intensity Difference (%PID) >= 50% from baseline to endpoint [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  Pain intensity will be measured using a numeric rating scale (NRS), from 0 (no pain) to 10 (worst pain imaginable).
  
  

• The change from baseline in mean pain intensity [ Time Frame: Baseline, Week 12 ] [ Designated as safety issue: No ]
  Pain intensity will be measured using a numeric rating scale (NRS), from 0 (no pain) to 10 (worst pain imaginable).
  
  
• The difference between the patient's pain treatment goal set at baseline [ Time Frame: Baseline, Week 12 ] [ Designated as safety issue: No ]
  The degree of pain the patient wishes to achieve by the end of treatment, set at baseline. The degree of pain will be measured using a numeric rating scale (NRS), from 0 (no pain) to 10 (worst pain imaginable).
  
  
• The degree of night sleep disturbance due to pain [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  Sleep disturbance due to pain will be measured using a Numeric Rating Scale (NRS): 1 = None, 10 = Complete.
  
  
• The degree of Interference with Daily Life Performance due to Pain [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  The degree of interference with daily life performance due to pain will be assessed on a 5-point scale: 1 = No interference, 5 = Great interference. Daily life performance means household work performance, etc.
  
  
• The degree of Interference with Social Life Performance due to Pain [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  The degree of interference with social life performance due to pain will be measured on a 5-point scale; 1 = No interference, 5 = Great interference. Social life performance means interpersonal relationship, going out, working life, etc.
  
  
• The patient's global assessment of pain treatment [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  The patient will assess on a 5-point scale (1= not effective, 5= greatly effective) how effective the study drug has been in the judgment of the study participant.
  
  
• The investigator's global assessment of pain treatment [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  The investigator will assess on a 5-point scale (1= not effective, 5= greatly effective) how effective the study drug has been for a patient, in the judgment of the investigator.
  
  

This is a multicenter, prospective (a study in which the patients are identified and then followed forward in time for the outcome of the study), open-label (all people know the identity of the intervention), observational study intended to examine the effectiveness of Fentanyl matrix through the degree of improvement of pain. Fentanyl matrix is a transdermal (through the skin) system providing continuous delivery of fentanyl for 72 hours. Fentanyl matrix will be administered to patients with chronic (prolonged) non-cancer pain under routine practice during 12 weeks. Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.